FOI 23/032 – product Eylea PBRER
13 January 2023

we would like to request additional information for "Eylea (aflibercept)".
Requesting document is listed below and please let me know if you need additional information.

Requesting documents	*Documents requesting for freedom of information (FOI) of the product name 'Eylea'* *▶ PBRER body (the latest one)*

MHRA response
9 March 2023

Please accept our apologies for the delay in responding to your request. We can confirm that the MHRA does hold the requested document and a copy is attached.

Information that has been redacted is exempt under Section 40 (Personal Information) of the Freedom of Information (FOI) Act and is therefore withheld.

Section 40 provides that personal information may be exempt from release where to do so would contravene data protection principles. Furthermore, we do not believe that there is an overriding public interest in disclosing the redacted information in this instance.

We hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Please remember to quote the reference number above in any future communications.

Yours sincerely,

FOI Team,
Safety & Surveillance Group
Medicines and Healthcare Products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU